查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1675648

抗結核病治療市場報告，按疾病類型（活動性結核病、潛伏性結核病和其他）、診斷和治療（診斷、治療）、最終用戶（醫院、專科診所、家庭護理和其他）和地區分類，2025 年至 2033 年

Anti-Tuberculosis Therapeutics Market Report by Disease Type (Active TB, Latent TB, and Others), Diagnosis and Treatment (Diagnosis, Treatment), End User (Hospitals, Specialty Clinics, Homecare, and Others), and Region 2025-2033
出版日期: | 出版商: IMARC | 英文 146 Pages | 商品交期: 2-3個工作天內

價格

2024IMARC Group全球抗結核治療市場規模達到 15.301 億美元。醫療支出的增加、優惠的報銷政策、技術進步以及不斷發展的公私合作夥伴關係是推動市場發展的一些關鍵因素。

抗結核治療是指用於治療結核病（TB）的藥物和治療策略，結核病是一種由結核分枝桿菌引起的細菌感染。結核病主要影響肺部，也可擴散至身體的其他部位，如腎臟、脊椎和腦部。抗結核療法用於消滅體內的細菌並防止感染的擴散。這是透過聯合使用通常需要六至九個月的抗生素來實現的。一些最常用的藥物包括異煙肼、利福平、乙胺丁醇和吡嗪醯胺。所用藥物的具體組合取決於感染的嚴重程度和患者的健康狀況。此外，定期監測和追蹤對於確保治療成功和防止抗藥性結核病的發展也至關重要。近年來，抗結核治療越來越受到關注，因為它還涉及支持性護理，例如氧氣療法、營養支持和可能出現的併發症的管理。

抗結核治療市場趨勢：

推動市場發展的主要因素之一是全球結核病（TB）的高發生率，尤其是在中低收入國家。此外，由於治療不完善、醫療基礎設施不足以及缺乏適當的醫療保健而導致的抗藥性結核病發病率不斷增加，對市場成長產生了積極影響。除此之外，新藥和治療策略的發展也推動了抗結核治療市場的發展。近年來，貝達喹啉、德拉馬尼等多種新藥已獲批准用於治療結核病。與傳統結核病藥物相比，這些藥物的療效和安全性均有所提升。同時，技術和診斷技術的進步使得結核病能夠早期發現和診斷，從而及時開始治療並獲得更好的患者治療效果，這是另一個主要的成長誘導因素。此外，特別是新興經濟體的醫療支出增加，改善了醫療基礎設施，增加了獲得優質醫療服務的機會，包括結核病治療。除此之外，人們對結核病的認知不斷提高以及早期診斷和治療的重要性也增加了對抗結核病治療的需求。此外，政府對結核病控制計畫的措施和資助在推動抗結核治療市場方面發揮了重要作用。例如，政府和非政府組織 (NGO) 正在共同努力提高意識、改善診斷並確保獲得負擔得起且有效的治療，預計將在未來幾年推動市場成長。

本報告回答的關鍵問題：

  • 全球抗結核治療市場迄今表現如何？
  • 全球抗結核治療市場的促進因素、限制因素和機會有哪些？
  • 每個促進因素、限制因素和機會對全球抗結核治療市場有何影響？
  • 主要的區域市場有哪些？
  • 哪些國家擁有最具吸引力的抗結核治療市場？
  • 根據疾病類型，市場分佈如何？
  • 抗結核病治療市場上最具吸引力的疾病類型是哪一種？
  • 根據診斷和治療，市場如何分類？
  • 抗結核治療市場上最具吸引力的診斷和治療方法是什麼？
  • 根據最終用戶，市場分佈如何？
  • 抗結核治療市場中最具吸引力的最終用戶是誰？
  • 全球抗結核治療市場的競爭結構是怎麼樣的？
  • 全球抗結核治療市場的主要參與者/公司有哪些？

目錄

第 1 章：前言

第 2 章：範圍與方法

  • 研究目標
  • 利害關係人
  • 資料來源
    • 主要來源
    • 次要來源
  • 市場評估
    • 自下而上的方法
    • 自上而下的方法
  • 預測方法

第 3 章：執行摘要

第 4 章：簡介

  • 概述
  • 主要行業趨勢

第 5 章：全球抗結核治療市場

  • 市場概況
  • 市場表現
  • COVID-19 的影響
  • 市場預測

第 6 章：市場區隔：依疾病類型

  • 活動性結核病
  • 潛伏性結核病
  • 其他

第7章：市場分化：診斷與治療

  • 診斷
    • 關鍵部分
      • 血液檢查
      • 影像學檢查
      • 痰液偵測
      • 其他
  • 治療
    • 關鍵部分
      • 一線藥物
        • 主要類型
          • 異煙肼
          • 乙胺丁醇
          • 利福平
          • 其他
      • 二線藥物
        • 主要類型
          • 硫乙醯酮
          • 對氨基水楊酸 (PAS)
          • 其他
      • 其他

第 8 章：市場區隔：依最終用戶

  • 醫院
  • 專科診所
  • 居家護理
  • 其他

第9章：市場細分：依地區

  • 北美洲
    • 美國
    • 加拿大
  • 亞太
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 其他
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 俄羅斯
    • 其他
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他
  • 中東和非洲
    • 市場區隔：依國家

第 10 章：促進因素、限制因素與機遇

  • 概述
  • 驅動程式
  • 限制
  • 機會

第 11 章：價值鏈分析

第 12 章：波特五力分析

  • 概述
  • 買家的議價能力
  • 供應商的議價能力
  • 競爭程度
  • 新進入者的威脅
  • 替代品的威脅

第 13 章：價格分析

第 14 章：競爭格局

  • 市場結構
  • 關鍵參與者
  • 關鍵參與者簡介
    • F. Hoffmann-La Roche Ltd.
    • Lannett Company Inc.
    • Lupin Limited
    • Macleods Pharmaceuticals Limited
    • Otsuka Pharmaceutical Co. Ltd
Product Code: SR112025A7629

The global anti-tuberculosis therapeutics market size reached USD 1,530.1 Million in 2024. Looking forward, IMARC Group expects the market to reach USD 2,552.2 Million by 2033, exhibiting a growth rate (CAGR) of 5.56% during 2025-2033. The rising healthcare spending, favorable reimbursement policies, technological advancements, and growing public-private partnerships represent some of the key factors driving the market.

Anti-tuberculosis therapeutics refer to the drugs and treatment strategies used to manage tuberculosis (TB), a bacterial infection caused by Mycobacterium tuberculosis. TB primarily affects the lungs and can also spread to other parts of the body, such as the kidneys, spine, and brain. Anti-tuberculosis therapeutics are used to eradicate the bacteria from the body and prevent the spread of the infection. This is achieved through a combination of antibiotics that are typically prescribed for six to nine months. Some of the most commonly used drugs include isoniazid, rifampin, ethambutol, and pyrazinamide. The exact combination of drugs used depends on the severity of the infection and the patient's health status. In addition, regular monitoring and follow-up are also essential to ensure treatment success and prevent the development of drug-resistant TB. In recent years, anti-tuberculosis therapeutics have gained traction as it also involves supportive care, such as oxygen therapy, nutrition support, and management of complications that may arise.

Anti-Tuberculosis Therapeutics Market Trends:

One of the primary factors driving the market is the high prevalence of tuberculosis (TB) worldwide, particularly in low- and middle-income countries. Additionally, the growing incidence of drug-resistant TB due to incomplete treatment, inadequate healthcare infrastructure, and lack of access to appropriate healthcare is positively influencing the market growth. Other than this, the development of new drugs and treatment strategies is also driving the anti-tuberculosis therapeutics market. In recent years, several new drugs, such as bedaquiline and delamanid, have been approved for the treatment of TB. These drugs offer improved efficacy and safety profiles compared to traditional TB drugs. In line with this, advancements in technology and diagnostics have enabled early detection and diagnosis of TB, leading to timely initiation of treatment and better patient outcomes, which represents another major growth-inducing factor. Furthermore, the increase in healthcare spending, particularly in emerging economies, has led to improved healthcare infrastructure and increased access to quality healthcare, including TB treatment. Apart from this, the growing awareness about TB and the importance of early diagnosis and treatment has also escalated the demand for anti-tuberculosis therapeutics. Moreover, government initiatives and funding for TB control programs have played a significant role in driving the anti-tuberculosis therapeutics market. For instance, governments and non-governmental organizations (NGOs) are working together to increase awareness, improve diagnosis, and ensure access to affordable and effective treatments, which is expected to drive market growth in the upcoming years.

Key Market Segmentation:

Disease Type Insights:

  • Active TB
  • Latent TB
  • Others

Diagnosis and Treatment Insights:

  • Diagnosis
  • Blood Tests
  • Imaging Tests
  • Sputum Tests
  • Others
  • Treatment
  • First-Line of Drugs
  • Isoniazid
  • Ethambutol
  • Rifampin
  • Others
  • Second-Line of Drugs
  • Thiacetazone
  • Paraaminosalicyclic Acid (PAS)
  • Others
  • Others

End User Insights:

  • Hospitals
  • Specialty Clinics
  • Homecare
  • Others

Regional Insights:

  • North America
  • United States
  • Canada
  • Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
  • Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
  • Latin America
  • Brazil
  • Mexico
  • Others
  • Middle East and Africa
  • The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America was the largest market for anti-tuberculosis therapeutics. Some of the factors driving the North America anti-tuberculosis therapeutics market included rising prevalence of tuberculosis, growing drug resistance, and numerous government initiatives.

Competitive Landscape:

  • The report has also provided a comprehensive analysis of the competitive landscape in the global anti-tuberculosis therapeutics market. Detailed profiles of all major companies have also been provided. Some of the companies covered include F Hoffmann-La Roche Ltd., Lannett Company Inc., Lupin Limited, Macleods Pharmaceuticals Limited, Otsuka Pharmaceutical Co. Ltd., etc. Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

Key Questions Answered in This Report:

  • How has the global anti-tuberculosis therapeutics market performed so far, and how will it perform in the coming years ?
  • What are the drivers, restraints, and opportunities in the global anti-tuberculosis therapeutics market ?
  • What is the impact of each driver, restraint, and opportunity on the global anti-tuberculosis therapeutics market ?
  • What are the key regional markets ?
  • Which countries represent the most attractive anti-tuberculosis therapeutics market ?
  • What is the breakup of the market based on the disease type ?
  • Which is the most attractive disease type in the anti-tuberculosis therapeutics market ?
  • What is the breakup of the market based on the diagnosis and treatment ?
  • Which is the most attractive diagnosis and treatment in the anti-tuberculosis therapeutics market ?
  • What is the breakup of the market based on end user ?
  • Which is the most attractive end user in the anti-tuberculosis therapeutics market ?
  • What is the competitive structure of the global anti-tuberculosis therapeutics market ?
  • Who are the key players/companies in the global anti-tuberculosis therapeutics market ?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Anti-Tuberculosis Therapeutics Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Disease Type

  • 6.1 Active TB
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Latent TB
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Others
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast

7 Market Breakup by Diagnosis and Treatment

  • 7.1 Diagnosis
    • 7.1.1 Market Trends
    • 7.1.2 Key Segments
      • 7.1.2.1 Blood Tests
      • 7.1.2.2 Imaging Tests
      • 7.1.2.3 Sputum Tests
      • 7.1.2.4 Others
    • 7.1.3 Market Forecast
  • 7.2 Treatment
    • 7.2.1 Market Trends
    • 7.2.2 Key Segments
      • 7.2.2.1 First-Line of Drugs
        • 7.2.2.1.1 Major Types
          • 7.2.2.1.1.1 Isoniazid
          • 7.2.2.1.1.2 Ethambutol
          • 7.2.2.1.1.3 Rifampin
          • 7.2.2.1.1.4 Others
      • 7.2.2.2 Second-Line of Drugs
        • 7.2.2.2.1 Major Types
          • 7.2.2.2.1.1 Thiacetazone
          • 7.2.2.2.1.2 Paraaminosalicyclic Acid (PAS)
          • 7.2.2.2.1.3 Others
      • 7.2.2.3 Others
    • 7.2.2 Market Forecast

8 Market Breakup by End User

  • 8.1 Hospitals
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Specialty Clinics
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Homecare
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Others
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia-Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 Drivers, Restraints, and Opportunities

  • 10.1 Overview
  • 10.2 Drivers
  • 10.3 Restraints
  • 10.4 Opportunities

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 F. Hoffmann-La Roche Ltd.
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
      • 14.3.1.3 SWOT Analysis
    • 14.3.2 Lannett Company Inc.
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
      • 14.3.2.3 Financials
      • 14.3.2.4 SWOT Analysis
    • 14.3.3 Lupin Limited
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
      • 14.3.3.3 Financials
      • 14.3.3.4 SWOT Analysis
    • 14.3.4 Macleods Pharmaceuticals Limited
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
    • 14.3.5 Otsuka Pharmaceutical Co. Ltd
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio

Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

List of Figures

  • Figure 1: Global: Anti-Tuberculosis Therapeutics Market: Major Drivers and Challenges
  • Figure 2: Global: Anti-Tuberculosis Therapeutics Market: Sales Value (in Million USD), 2019-2024
  • Figure 3: Global: Anti-Tuberculosis Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 4: Global: Anti-Tuberculosis Therapeutics Market: Breakup by Disease Type (in %), 2024
  • Figure 5: Global: Anti-Tuberculosis Therapeutics Market: Breakup by Diagnosis and Treatment (in %), 2024
  • Figure 6: Global: Anti-Tuberculosis Therapeutics Market: Breakup by End User (in %), 2024
  • Figure 7: Global: Anti-Tuberculosis Therapeutics Market: Breakup by Region (in %), 2024
  • Figure 8: Global: Anti-Tuberculosis Therapeutics (Active TB) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 9: Global: Anti-Tuberculosis Therapeutics (Active TB) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 10: Global: Anti-Tuberculosis Therapeutics (Latent TB) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 11: Global: Anti-Tuberculosis Therapeutics (Latent TB) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 12: Global: Anti-Tuberculosis Therapeutics (Other Disease Types) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 13: Global: Anti-Tuberculosis Therapeutics (Other Disease Types) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 14: Global: Anti-Tuberculosis Therapeutics (Diagnosis) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 15: Global: Anti-Tuberculosis Therapeutics (Diagnosis) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 16: Global: Anti-Tuberculosis Therapeutics (Treatment) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 17: Global: Anti-Tuberculosis Therapeutics (Treatment) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 18: Global: Anti-Tuberculosis Therapeutics (Hospitals) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 19: Global: Anti-Tuberculosis Therapeutics (Hospitals) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 20: Global: Anti-Tuberculosis Therapeutics (Specialty Clinics) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 21: Global: Anti-Tuberculosis Therapeutics (Specialty Clinics) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 22: Global: Anti-Tuberculosis Therapeutics (Homecare) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 23: Global: Anti-Tuberculosis Therapeutics (Homecare) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 24: Global: Anti-Tuberculosis Therapeutics (Other End Users) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 25: Global: Anti-Tuberculosis Therapeutics (Other End Users) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 26: North America: Anti-Tuberculosis Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 27: North America: Anti-Tuberculosis Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 28: United States: Anti-Tuberculosis Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 29: United States: Anti-Tuberculosis Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 30: Canada: Anti-Tuberculosis Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 31: Canada: Anti-Tuberculosis Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 32: Asia-Pacific: Anti-Tuberculosis Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 33: Asia-Pacific: Anti-Tuberculosis Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 34: China: Anti-Tuberculosis Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 35: China: Anti-Tuberculosis Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 36: Japan: Anti-Tuberculosis Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 37: Japan: Anti-Tuberculosis Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 38: India: Anti-Tuberculosis Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 39: India: Anti-Tuberculosis Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 40: South Korea: Anti-Tuberculosis Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 41: South Korea: Anti-Tuberculosis Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 42: Australia: Anti-Tuberculosis Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 43: Australia: Anti-Tuberculosis Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 44: Indonesia: Anti-Tuberculosis Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 45: Indonesia: Anti-Tuberculosis Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 46: Others: Anti-Tuberculosis Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 47: Others: Anti-Tuberculosis Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 48: Europe: Anti-Tuberculosis Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 49: Europe: Anti-Tuberculosis Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 50: Germany: Anti-Tuberculosis Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 51: Germany: Anti-Tuberculosis Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 52: France: Anti-Tuberculosis Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 53: France: Anti-Tuberculosis Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 54: United Kingdom: Anti-Tuberculosis Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 55: United Kingdom: Anti-Tuberculosis Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 56: Italy: Anti-Tuberculosis Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 57: Italy: Anti-Tuberculosis Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 58: Spain: Anti-Tuberculosis Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 59: Spain: Anti-Tuberculosis Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 60: Russia: Anti-Tuberculosis Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 61: Russia: Anti-Tuberculosis Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 62: Others: Anti-Tuberculosis Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 63: Others: Anti-Tuberculosis Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 64: Latin America: Anti-Tuberculosis Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 65: Latin America: Anti-Tuberculosis Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 66: Brazil: Anti-Tuberculosis Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 67: Brazil: Anti-Tuberculosis Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 68: Mexico: Anti-Tuberculosis Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 69: Mexico: Anti-Tuberculosis Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 70: Others: Anti-Tuberculosis Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 71: Others: Anti-Tuberculosis Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 72: Middle East and Africa: Anti-Tuberculosis Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 73: Middle East and Africa: Anti-Tuberculosis Therapeutics Market: Breakup by Country (in %), 2024
  • Figure 74: Middle East and Africa: Anti-Tuberculosis Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 75: Global: Anti-Tuberculosis Therapeutics Industry: Drivers, Restraints, and Opportunities
  • Figure 76: Global: Anti-Tuberculosis Therapeutics Industry: Value Chain Analysis
  • Figure 77: Global: Anti-Tuberculosis Therapeutics Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Anti-Tuberculosis Therapeutics Market: Key Industry Highlights, 2024 & 2033
  • Table 2: Global: Anti-Tuberculosis Therapeutics Market Forecast: Breakup by Disease Type (in Million USD), 2025-2033
  • Table 3: Global: Anti-Tuberculosis Therapeutics Market Forecast: Breakup by Diagnosis and Treatment (in Million USD), 2025-2033
  • Table 4: Global: Anti-Tuberculosis Therapeutics Market Forecast: Breakup by End User (in Million USD), 2025-2033
  • Table 5: Global: Anti-Tuberculosis Therapeutics Market Forecast: Breakup by Region (in Million USD), 2025-2033
  • Table 6: Global: Anti-Tuberculosis Therapeutics Market: Competitive Structure
  • Table 7: Global: Anti-Tuberculosis Therapeutics Market: Key Players